Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M

MARAVAI LIFESCIENCES HOLDINGS, INC.

2021-Q2 EPS reported $0.69 revenue$365,986,000

Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.
Nucleic Acid Production revenue $192.5M (+532.8% YoY) driven by CleanCap demand for COVID-19 vaccines.
Divested Protein Detection segment (Vector) for $124M cash to Thompson Street Capital Partners; close expected Q3 2021.
2021 revenue guidance raised to $745-770M from prior; reflects robust demand for Nucleic Acid Production.
Facility expansions: new San Diego site to boost mRNA capacity; Biologic Safety Testing moving to larger Leland, NC site.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.